학술논문
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Document Type
Article
Author
Adams, Atoya; Andrews, Jane M; Behrend, Clint E; Brown, Gregor J E; Chen Yi Mei, Swee Lin; Coates, Allan G; DiMarino, Anthony J; Ee, Hooi; Elliott, David E; Epstein, Roger M; Feyen, Bryan John; Fogel, Ronald P; Friedenberg, Keith Alan; Gearry, Richard B; Gerdis, Michael S; Goldstein, Michael J; Gupta, Vipin K; Holmes, Robert John; Holtmann, Gerald J; Idarraga, Samuel H; James, George W; King, Tim; Klein, Terry D; Kupfer, Sonia S; Lebwohl, Benjamin; Lowe, Matthew John; Murray, Joseph A; Newton, Eric B; Quinn, Dean; Radin, David M; Ritter, Timothy E; Stacey, Helen Lee; Strout, Cynthia B; Stubbs, Richard S; Thackwray, Susan Lynn; Trivedi, Vivek M; Weber, John R; Wilson, Scott A; Tye-Din, Jason A; Daveson, A James M; Goel, Gautam; Goldstein, Kaela E; Hand, Holly L; Neff, Kristin M; Popp, Alina; Taavela, Juha; Maki, Markku; Isola, Jorma; Williams, Leslie J; Truitt, Kenneth E; Anderson, Robert P
Source
In The Lancet Gastroenterology & Hepatology May 2023 8(5):446-457
Subject
Language
ISSN
2468-1253